Antigen-specific IgG elicited in subjects with prostate cancer treated with Flt3 ligand

Journal of Immunotherapy

Volumn 28, Issue 3, 2005, Pages 268-275

  Dunphy, Edward J ^a   McNeel, Douglas G ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Antigens; Flt3 ligand; IgG; Prostate cancer; SEREX

Indexed keywords

FLT3 LIGAND; IMMUNOGLOBULIN G; PROSTATE ANTIGEN; TUMOR ANTIGEN;

ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA LIBRARY; DRUG EFFICACY; HUMAN; HYPOTHYROIDISM; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS;

EID: 17844380225     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cji.0000158853.15664.0c     Document Type: Article

References (26)

1. McNeel DG, Disis ML. Tumor vaccines for the management of prostate cancer. Arch Immunol Ther Exp. 2000;48:85-93.
2. Dunphy EJ, Eickhoff JC, Muller CH, et al. Identification of antigen-specific IgG in sera from patients with chronic prostatitis. J Clin Immunol. 2004;24:492-501.
3. Esche C, Subbotin VM, Maliszewski C, et al. FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res. 1998;58:380-383.
4. Chen K, Braun S, Lyman S, et al. Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res. 1997;57:3511-3516.
5. Ciavarra RP, Somers KD, Brown RR, et al. Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer. Cancer Res. 2000;60:2081-2084.
6. Higano CS, Vogelzang NJ, Sosman JA, et al. Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer. Clin Cancer Res. 2004;10:1219-1225.
7. McNeel DG, Knutson KL, Schiffman K, et al. Pilot study of an HLA-A2 peptide vaccine using Flt3 ligand as a systemic vaccine adjuvant. J Clin Immunol. 2003;23:62-72.
8. McNeel DG, Nguyen LD, Storer BE, et al. Antibody immunity to prostate cancer-associated antigens can be detected in the serum of patients with prostate cancer. J Urol. 2000;164:1825-1829.
9. Nagase T, Kikuno R, Ishikawa KI, et al. Prediction of the coding sequences of unidentified human genes. XVI. The complete sequences of 150 new cDNA clones from brain which code for large proteins in vitro. DNA Res. 2000;7:65-73.
10. Strausberg RL, Feingold EA, Grouse LH, et al. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci USA. 2002;99:16899-16903.
11. McNeel DG, Nguyen LD, Ellis WJ, et al. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. Prostate. 2001;47:222-229.
12. Saffran DC, Reiter RE, Jakobovits A, et al. Target antigens for prostate cancer immunotherapy. Cancer Metastasis Rev. 1999;18:437-449.
13. Storkus WJ, Zeh HJ 3rd, Maeurer MJ, et al. Identification of human melanoma peptides recognized by class I restricted turner infiltrating T lymphocytes. J Immunol. 1993;151:3719-3727.
14. van der Bruggen P, Traversar C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643-1647.
15. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA. 1995;92:11810-11813.
16. Jäger E, Chen YT, Drijfhout JW, et al. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-hinding peptide epitopes. J Exp Med. 1998;187:265-270.
17. Valmori D, Dutoit V, Lienard D, et al. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 2000;60:4499-4506.
18. Tureci O, Sahin U, Pfreundschuh M. Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today. 1997;3:342-349.
19. Tureci O, Sahin U, Zwick C, et al. Exploitation of the antibody repertoire of cancer patients for the identification of human tumor antigens. Hybridoma. 1999;18:23-28.
20. Okada H, Attanucci J, Giezeman-Smits KM, et al. Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo. Cancer Res. 2001;61:2625-2631.
21. Hodi FS, Schmollinger JC, Soiffer RJ, et al. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci USA. 2002;99:6919-6924.
22. Angelopoulou K, Rosen B, Stratis M, et al. Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival. Cancer. 1996;78:2146-2152.
23. Lang C, Unteregger G, Kartarius S, et al. p53 autoantibodies in patients with urological tumours. Br J Urol. 1998;82:721-726.
24. Garkavtsev I, Kozin SV, Chernova O, et al. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature. 2004;428:328-332.
25. Heinz S, Krause SW, Gabrielli F, et al. Genomic organization of the human gene HEP27: alternative promoter usage in HepG2 cells and monocyte-derived dendritic cells. Genomics. 2002;79:608-615.
26. Troester MA, Hoadley KA, Sorlie T, et al. Cell-type-specific responses to chemotherapeutics in breast cancer. Cancer Res. 2004;64:4218-4226.